Trial · NCT01705509
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
NCT01705509, Not applicable, Terminated, Cardiovascular Institute of the South Clinical Research Corporation; results first posted 2020-02-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC). Trials, record NCT01705509. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01705509
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
- NCT number
- NCT01705509
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 14 participants, actual
- Lead sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
- Conditions
- Cardiomyopathy
- Interventions
- Ranolazine
- First posted
- 2012-10-12
- Last updated
- 2020-02-18
- Results first posted
- 2020-02-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cardiopulmonary Exercise Test Parameters (CPET). | 30 days | CPET parameters assessed will include the peak VO2: measures the peak transport of O2 to the tissues when O2 extraction from the blood is maximal; 2) the anaerobic threshold (AT): measures the sustainable work capacity in units of VO2; 3) the O2-pulse measurements at the AT and peak VO2: estimate stroke volume at those levels of exercise; and 4) the relationship of O2 uptake to work rate (ΔVO2/ΔWR): provides information on the ability of the cardiac output to increase. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cardiopulmonary Exercise Test Parameters (CPET). | 30 days | Number of Participants who Reached CPET Milestones | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cardiopulmonary Exercise Test Parameters (CPET). | Control | Failed Initial CPET | 5 | Participants | |
| Cardiopulmonary Exercise Test Parameters (CPET). | Control | Withdrew Prior to CPET | 2 | Participants | |
| Cardiopulmonary Exercise Test Parameters (CPET). | Control | Screenfailed due to Ranolazine Intolerance | 2 | Participants | |
| Cardiopulmonary Exercise Test Parameters (CPET). | Control | Completed | 5 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Inclusion CPET | STARTED | CPET Control / CPET With Ranexa | 14 | |
| Inclusion CPET | COMPLETED | CPET Control / CPET With Ranexa | 7 | |
| Inclusion CPET | NOT COMPLETED | CPET Control / CPET With Ranexa | 7 | |
| CPET w/ Ranexa | STARTED | CPET Control / CPET With Ranexa | 7 | |
| CPET w/ Ranexa | COMPLETED | CPET Control / CPET With Ranexa | 5 | |
| CPET w/ Ranexa | NOT COMPLETED | CPET Control / CPET With Ranexa | 2 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | CAD (Ranexa 1000mg BID Treatment) | Cardiac disorders | CPET Control / CPET With Ranexa | 1 | 14 | 1 |
| other | Ranexa Intolerant (Ranexa 1000mg BID Treatment) | General disorders | CPET Control / CPET With Ranexa | 2 | 14 | 2 |
| other | Headache (Ranexa 1000mg BID Treatment) | General disorders | CPET Control / CPET With Ranexa | 1 | 14 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CPET Control / CPET With Ranexa | 0 | 14 |
| Total, other adverse events | CPET Control / CPET With Ranexa | 4 | 14 |
| Total, serious adverse events | CPET Control / CPET With Ranexa | 0 | 14 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01705509
GET https://conductscience.org/api/trials/v1/NCT01705509/registered